BenevolentAI SPAC Presentation Deck

Clear path for monetisation depending on the profile of each asset out of BenevolentAl's platform Commercialised Pipeline Assets B Pipeline Assets to be Out-Licensed *based on GlobalData D Glioblastoma / Other Oncology D Ulcerative Colitis / IBD Antiviral Unidentified Targets Amyotrophic Lateral Sclerosis Atopic Dermatitis Non-Alcoholic Steatohepatitis (NASH) Parkinson's Disease Unidentified Targets Internal Clinical development Performance-based payments to Benevolent Al (illustrative*) Development Milestones ~$275m Pre-Phase I (IND) Post-Phase I Post-Phase II Upfront ~$10m ~$80m ~$100m ~$325m Commercialisation ~$350m Royalties ~8% ~12% ~15% Benevolent 33

View entire presentation